Cogent Biosciences, Inc. (COGT) Financial Statements (2026 and earlier)

Company Profile

Business Address 275 WYMAN STREET
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments900,765287,077265,710259,276219,684242,190
Cash and cash equivalent312,01298,16553,229139,886219,684242,190
Short-term investments588,753188,912212,481119,390  
Restricted cash and investments    1,255  
Other undisclosed current assets9,5909,3955,0614,4352,9492,722
Total current assets:910,355296,472270,771264,966222,633244,912
Noncurrent Assets
Operating lease, right-of-use asset18,07820,09721,99823,3162,7714,615
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization5,4576,4678,3447,7831,706134
Long-term investments and receivables   7,460   
Long-term investments   7,460   
Restricted cash and investments416   1,2551,255
Other noncurrent assets3,3014,8624,8644,7453,727 
Total noncurrent assets:27,25231,42642,66635,8449,4596,004
TOTAL ASSETS:937,607327,898313,437300,810232,092250,916
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:31,98924,64520,97012,3097,1074,779
Employee-related liabilities✕✕✕✕✕3,3891,443
Accounts payable9,50412,01310,6555,8423,483732
Accrued liabilities22,48512,63210,3156,467235984
Other undisclosed accounts payable and accrued liabilities      1,620
Other undisclosed current liabilities31,96431,06517,19814,5409,9708,315
Total current liabilities:63,95355,71038,16826,84917,07713,094
Noncurrent Liabilities
Long-term debt and lease obligation222,895   8313,155
Long-term debt, excluding current maturities222,895     
Liabilities, other than long-term debt14,38815,90217,46718,226  
Other liabilities33     
Operating lease, liability14,35515,90217,46718,2268313,155
Other undisclosed noncurrent liabilities     (831)(3,155)
Total noncurrent liabilities:237,28315,90217,46718,2268313,155
Total liabilities:301,23671,61255,63545,07517,90816,249
Equity
Equity, attributable to parent, including:636,371256,286257,802255,735214,184234,667
Common stock16111086704432
Additional paid in capital1,734,8821,004,612801,059601,153399,713322,454
Accumulated other comprehensive income (loss)355447246(104)  
Accumulated deficit(1,188,420)(859,483)(603,624)(411,214)(270,973)(198,700)
Other undisclosed equity, attributable to parent89,393110,60060,03565,83085,400110,881
Total equity:636,371256,286257,802255,735214,184234,667
TOTAL LIABILITIES AND EQUITY:937,607327,898313,437300,810232,092250,916

Income Statement (P&L) ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues   9502,6212,4687,871
Sublease income   9502,6212,468770
Cost of revenue      (49,518)
Gross profit:   9502,6212,468(41,647)
Operating expenses(333,363)(275,939)(208,130)(147,839)(75,551)(40,552)
Other undisclosed operating loss   (950)(2,621)(2,468) 
Operating loss:(333,363)(275,939)(208,130)(147,839)(75,551)(82,199)
Nonoperating income4,42620,08015,7207,5983,2787,391
Investment income, nonoperating14,68918,08813,0773,989467144
Other nonoperating income (expense)(20)1,9929432,2492,468779
Interest and debt expense(7,181)     
Loss from continuing operations:(336,118)(255,859)(192,410)(140,241)(72,273)(74,808)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(72,273)(74,808)
Other undisclosed net income7,181     
Net loss:(328,937)(255,859)(192,410)(140,241)(72,273)(74,808)
Other undisclosed net income attributable to parent      
Net loss attributable to parent:(328,937)(255,859)(192,410)(140,241)(72,273)(74,808)
Other undisclosed net loss available to common stockholders, basic      (104,400)
Net loss available to common stockholders, diluted:(328,937)(255,859)(192,410)(140,241)(72,273)(179,208)

Comprehensive Income ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(328,937)(255,859)(192,410)(140,241)(72,273)(74,808)
Other comprehensive income (loss)(92)201350(104)  
Comprehensive loss:(329,029)(255,658)(192,060)(140,345)(72,273)(74,808)
Other undisclosed comprehensive income, net of tax, attributable to parent      
Comprehensive loss, net of tax, attributable to parent:(329,029)(255,658)(192,060)(140,345)(72,273)(74,808)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: